N/A
Completed N=162
Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550
Arthritis, Rheumatoid
Source: ClinicalTrials.gov NCT00414661 ↗
Enrolled (actual)
162
Serious AEs
0.6%
Results posted
Jan 2013
Primary outcomePrimary: Incidence of Lymphoproliferative Disorders (LPD) — NA; NA; NA; NA LPD per 100 person-years
Summary
The purpose of this study is to follow the health of subjects who have previously been enrolled in studies of CP-690,550 for treatment of their rheumatoid arthritis. Subjects are only eligible for this study after they have completed all participation in other studies of CP-690,550.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence of Lymphoproliferative Disorders (LPD) |
NA; NA; NA; NA | — |
| PRIMARY Incidence of Lymphoma |
NA; NA; NA; NA | — |
| PRIMARY Incidence of Important Infections |
0.000; 0.607; 0.000; 0.000 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects who have completed all participation in any other Phase 2B or Phase 3 studies of CP-690,550 for rheumatoid arthritis.
Exclusion Criteria
- Any subject who refuses consent.
Data sourced from ClinicalTrials.gov (NCT00414661). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.